Skip to main content
Premium Trial:

Request an Annual Quote

Sequenom Revenues Drop 24 Percent, Losses Narrow in Q4

The revenue numbers in this article have been corrected from those reported earlier today.

 

NEW YORK, Feb. 10 (GenomeWeb News) - Sequenom today reported total reported that fourth-quarter revenues fell 24 percent to $6.1 million from $8 million for the year-ago quarter.

 

The company spent $3.9 million on R&D for the quarter, down from $6.4 million in the year-ago period.

 

The company cut its net loss to $6.9 million from $10.1 million for the fourth quarter of 2003, a 32-percent improvement for the San Diego-based company.

 

Sequenom reported cash and cash equivalents of $38 million as of Dec. 31, 2004.

 

Looking ahead, Sequenom said in 2005 it plans to launch a product with "enhanced multiplexing levels and advanced gene expression software," and release its first analyte specific reagents for public-domain genetic tests such as Factor V and cystic fibrosis.

 

Sequenom yesterday announced the resignation of CEO Toni Schuh.

The Scan

Support for Moderna Booster

An FDA advisory committee supports authorizing a booster for Moderna's SARS-CoV-2 vaccine, CNN reports.

Testing at UK Lab Suspended

SARS-CoV-2 testing at a UK lab has been suspended following a number of false negative results.

J&J CSO to Step Down

The Wall Street Journal reports that Paul Stoffels will be stepping down as chief scientific officer at Johnson & Johnson by the end of the year.

Science Papers Present Proteo-Genomic Map of Human Health, Brain Tumor Target, Tool to Infer CNVs

In Science this week: gene-protein-disease map, epigenomic and transcriptomic approach highlights potential therapeutic target for gliomas, and more